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ABSTRACT:  The DNA mismatch repair (MMR) pathway is essential in maintaining genomic 
stability through its role in DNA repair and the checkpoint response. Loss of DNA MMR underlies 
the hereditary cancer disease Lynch Syndrome (LS). Germline mutations in MSH2 account for 
approximately 40% of LS patients and of these, 18% are missense variants. One important clinical 
challenge has been discriminating between missense variants that are pathogenic and those that are 
not. Current analysis of missense mutations in MSH2 is performed using a combination of clinical, 
biochemical, and functional data; however, suitable cell culture models to test the various functions 
of the DNA MMR proteins are lacking. Here, we have generated human cell lines stably 
expressing a subset of MSH2 missense mutants and tested their effect on DNA repair and 
checkpoint response functions. We have expanded on previous biochemical and functional 
analyses performed in non-human systems to further understand defects conferred by this subset of 
single amino acid alterations. The functional characterization of MSH2 missense mutants 
combined with clinical and biochemical data is essential for appropriate patient management and 
genetic counseling decisions. ©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
The repair of single DNA nucleotide mismatches by the DNA mismatch repair (MMR) pathway is essential in 
maintaining genomic stability (Hsieh and Yamane, 2008; Li, 2008). Recognition of DNA basepair mismatches 
occurs by a heterodimer of two MutS homologs, MSH2 and MSH6. Models of MMR mechanism propose that 
MSH2-MSH6 heterodimers load onto DNA via a mismatch and then recruit downstream MMR factors including a 
heterodimer of the MutL homologues MLH1 and PMS2 (Acharya, et al., 2003; Constantin, et al., 2005; Zhang, et 
al., 2005).  In addition to their role in the repair of replication errors, these MMR proteins are required for the 
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activation of cell cycle checkpoints and apoptosis in response to DNA alkylation damage (Stojic, et al., 2004a).  
The requirement of MMR was initially characterized in MMR-deficient strains of E.coli, which displayed 
tolerance to the DNA alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (Karran and Marinus, 
1982). These observations were then extended to MMR-proficient human cell lines that were demonstrated to be 
100-fold more sensitive to treatment with MNNG than MMR-deficient cells (Karran, 2001). Activation of the 
DNA checkpoint response to low-doses of MNNG is mediated through the ATR-Chk1 pathway, which induces a 
G2 cell cycle arrest and subsequent apoptosis (Stojic, et al., 2004b).  
Inherited mutations in genes of the MMR pathway give rise to the autosomal dominant disorder Lynch 
Syndrome (LS; MIM# 120435), which accounts for 3-5% of all colorectal cancers. LS patients have a 60-80% 
chance of developing colorectal cancer in their lifetimes in addition to certain extracolonic cancers (Lynch, et al., 
2009).  The majority of LS patients carry a mutation in either MSH2 (MIM# 609309) or MLH1 (MIM# 120436), 
resulting primarily in a truncated, nonfunctional protein (Peltomaki and Vasen, 1997). However, of the mutations 
identified in MSH2, approximately 18% are missense mutations (Ou, et al., 2008). These single amino acid 
alterations are potentially powerful biological tools for understanding the mechanisms driving tumorigenesis in LS 
patients. We have previously investigated the in vitro biochemical defects associated with a subset of LS-
associated missense mutations in MSH2 using purified recombinant proteins (Heinen, et al., 2002). All but one of 
the missense mutant proteins examined conferred significant defects on MSH biochemical activity. However, these 
data do not directly address the impact of these mutations on MMR functions in the cell.  To date there has been 
limited data describing the contribution of MSH2 missense mutations on MMR functions in vivo. In this study we 
extend our previous work on four missense mutations in MSH2 to determine the consequences of their biochemical 
defects on in vivo repair and checkpoint response functions. 
 
MATERIALS AND METHODS 
Cell Culture and production of lentiviral cell lines  
Hec59 cells [kindly provided by Drs. Thomas Kunkel and Alan Clark (Watanabe, et al., 2000)] were grown in 
DMEM:Nutrient Mixture F-12 (DMEM/F-12), containing 10% fetal bovine serum (FBS; Gibco). cDNA from 
wild-type or missense MSH2 (GenBank NM_000251.1), including c.499G>C (p.Asp167His; D167H), c.1178A>T 
(p.Lys393Met; K393M), c.1571G>C (p.Arg524Pro; R524P), and c.1865C>T (p.Pro622Leu; P622L) generated 
previously (Heinen, et al., 2002), was PCR amplified and subcloned into the pCDH-EF1-MCS-T2A-Puro lentiviral 
expression vector (System Bioscience). All variant numbering is based on MSH2 cDNA sequence and uses the A 
of the ATG translation initiation start site as nucleotide +1. Following lentiviral transduction, puromycin was 
added to Hec59 cells at a final concentration of 0.5 μg/ml. Bulk-infected cell populations were kept under 
puromycin selection until harvest. Analyses were performed from two separate infections.  
 
Chemicals, Antibodies, and Reagents 
N-Methyl-N’-nitro-N-nitrosoguanidine (MNNG) was obtained from the National Cancer Institute Chemical 
Carcinogen Reference Standard Repository; CAS: 70-25-7. O
6-Benzylguanine (O
6-BG) and hydroxyurea were 
purchased from Sigma. Antibodies against PCNA (SC-56), MSH6 (SC-10798) and MSH3 (SC-11441) (for 
Western blot analyses) were purchased from Santa Cruz Biotechnology; MLH1 (550838 for Western blot 
analysis), MSH2 (556349 for Western blot analysis), MSH6 (610918 for immunoprecipitation) from BD 
Biosciences; Actin (A5060) from Sigma; Histone 3 (10799) from Abcam.  
 
Cell synchronization, drug treatment, and chromatin immunoprecipitation 
Synchronization at the G1/S boundary was performed by treatment with hydroxyurea (HU).  Cells were grown 
for 16 h in complete medium containing 2 mM HU, after which 25 μM O
6-BG was added until the cells were 
released into serum free medium containing 5 μM MNNG and 25 μM O
6-BG.  After 1 h, cells were incubated in 
complete medium until harvest. Chromatin immunoprecipitation (ChIP) was performed as previously described 
(Mastrocola and Heinen, 2010).  In Vivo Functions Affected by MSH2 Missense Mutations  E1701 
 
 
Cell Cycle and Survival Analyses 
Cell cycle analyses were performed using propidium iodide (PI) staining for DNA content with a FACS Calibur 
flow cytometer (BD Biosciences) and was analyzed by Modfit (Verity Software House). Time points were 
performed in duplicate.  For survival assays, 500 cells were plated then treated with 25 μM O
6-BG for 2 h 
followed by 0, 0.5, 2, 5, or 10 μM MNNG and 25 μM O
6-BG for one hour. Cells were incubated in normal growth 
media for 9 days. Subsequently, cells were harvested, fixed with methanol, and stained with crystal violet. The 
experiment was done in quadruplicate for each lentiviral cell line and time point. 
 
MMR Assay 
The heteroduplex MMR substrate was prepared according to Zhou et al. with modifications (Zhou, et al., 2009). 
The p111 and p189 plasmids were a kind gift from Dr. LuZhe Sun. p189 encodes for a premature stop codon in the 
EGFP gene. To generate single-stranded (ss) DNA, XL-1 blue cells were transformed with p111. Subsequently, 
cells were infected with the M13KO7 helper phage (New England Biolabs) to generate viral particles, which were 
recovered by polyethylenglycol 8000 precipitation. Phage particles were banded by CsCl ultracentrifugation and 
the ssDNA was isolated by phenol-chloroform extraction.  The MMR substrate was prepared by annealing the 
ssDNA circle to linearized, denatured DNA from p189. Excess ssDNA was removed by BND-cellulose. Excess 
dsDNA was removed by treatment with ExoV (USB). To assess MMR activity, cell lines were transfected with 1.5 
μg of the heteroduplex plasmid and 1 μg of red fluorescent protein (RFP) expressing plasmid pDsRed2-N1 
(Clonetech) using lipofectamine 2000. After incubation for 40 h the cells were harvested and analyzed for 
fluorescence intensity with a FACS LSRII-B flow cytometer (BD Biosciences) using BD FACSDiva software. 
GFP fluorescence was normalized to RFP expression to correct for differences in transfection efficiency. 
 
RESULTS 
 
Introduction and expression of MSH2 missense mutants in the MSH2-deficient cell line Hec59 
The goal of this study is to further understand the functional consequences of missense mutations in MSH2 on 
MMR functions in vivo. We chose to examine four missense mutations: D167H, K393M, R524P, and P622L 
(Figure 1A), which were identified in four different LS patients with microsatellite unstable tumors (Heinen, et al., 
2002; Leach, et al., 1993; Moslein, et al., 1996; Orth, et al., 1994). Stable Hec59 cell lines expressing MSH2 
missense mutant protein were derived using a lentiviral system that confers both MSH2 expression and resistance 
to puromycin (Donnelly, et al., 2001). Hec59 cells are an endometrial cancer cell line that carries biallelic 
mutations in MSH2 resulting in loss of a detectable protein product by Western blot (Figure 1B, lane 1).  Bulk 
populations of infected cells were kept under puromycin selection and protein expression from each cell 
population was determined by Western blot analysis (Figure 1B). MSH2 protein expression was found to be 
similar between the wild-type and mutant expressing cell lines, except for MSH2(P622L), which was ~50% of 
MSH2(WT).  In Hec59 cells the MSH6 and MSH3 proteins are also not detectable by Western blot as their 
stability depends on formation of a heterodimer with MSH2 (Marra, et al., 1998) (Figure 1B, lane 1), however, 
introduction of wild-type (WT) MSH2 restored both MSH6 and MSH3 stability. MSH2(D167H), MSH2(K393M), 
and MSH2(R524P) were also able to restore MSH6 and MSH3 protein stability while MSH2(P622L) did not 
(Figure 1B).  
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LS-associated missense mutations affect chromatin localization and MMR protein complex formation 
The recruitment and interaction of MMR proteins on the chromatin is an important step in the DNA MMR 
pathway  in vivo. We have previously shown that MSH2 and MLH1 rapidly accumulate and form a protein 
complex with PCNA on the chromatin following treatment with MNNG (Mastrocola and Heinen, 2010). DNA 
MMR activity is most abundant during S-phase (Schroering, et al., 2007), therefore, to monitor chromatin 
localization we first synchronized MSH2(WT) Hec59 cells to the G1/S border with hydroxyurea (HU), a 
ribonucleotide reductase inhibitor. We observed the majority of both DMSO and MNNG-treated cells in the 
middle of S-phase at 4 h post-HU release (Figure 2A). To monitor the localization of MMR proteins to the 
chromatin, chromatin-enriched fractions were prepared from the infected cell populations at 4h post-HU release. 
The parental Hec59 cells lack detectable MSH2 protein (Figure 2B, lane 1 and 2). The faint band displayed in the 
vector only chromatin-enriched fraction is nonspecific and is distinguishable from MSH2 under different SDS-
PAGE conditions (data not shown). A sub-population of wild-type MSH2 localizes to the chromatin during S-
phase and accumulates to an almost 3-fold greater extent upon treatment with MNNG (Figure 2B compare lanes 3 
and 4), whereas the MSH2(D167H) and MSH2(K393M) protein also localize to damaged chromatin to a slightly 
reduced extent (Figure 2B, lanes 6, 8) . Interestingly, MSH2(R524P) chromatin-bound levels were similar to the 
MSH2(WT) during an unperturbed cell cycle; however, MSH2(R524P) failed to accumulate after treatment with 
MNNG (Figure 2B compare lanes 4 and 10). In contrast, MSH2(P622L) failed to localize to the chromatin in 
damaged or undamaged cells (Figure 2B compare lanes 4 and 12).  
Reintroduction of MSH2(WT), MSH2(D167H) and MSH2(K393M) into Hec59 cells dramatically increased the 
chromatin-localization of MLH1 (Figure 2B), which is consistent with reports that MLH1 recruitment is MSH2-
dependent (Hidaka, et al., 2005; Mastrocola and Heinen, 2010). As expected, there were significantly reduced 
levels of chromatin-associated MLH1 in MSH2(R524P) and MSH2(P622L) cell populations.  Although we did not 
observe a significant difference in chromatin-associated PCNA levels in the MSH2(WT) cells after treatment with 
MNNG, we did observe a higher-migrating band on the PCNA blot that was significantly enhanced by DNA 
damage and may be a  mono-ubiquitinated (ub) form of PCNA (Szüts, et al., 2005).  We observed a similar 
increase in mono-ub PCNA in MSH(K393M) cells, but no increase for MSH2(R524P) and MSH2(P622L) cells 
populations. Interestingly, although MSH2(D167H) accumulated on damaged chromatin and was able to recruit 
MLH1, the levels of mono-ub PCNA were significantly diminished compared to the MSH2(WT) (Figure 2B 
compare lanes 4 and 8).    
 
Figure 1. Structural location and expression of MSH2 missense mutations. (A) MSH2 missense 
mutations mapped to the human MSH2-MSH6 crystal structure (Warren, et al., 2007). MSH6 is 
in pink, the subdomains of MSH2 are as indicated and mispaired DNA is lime green. (B) Whole 
cell extracts from Hec59 cells transduced with various lentiviral constructs were analyzed by 
Western blotting with antibodies against MSH2, MSH6, MSH3 or Actin as a loading control. 
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To test whether our subset of mutants are able to interact with MLH1 and PCNA in vivo, chromatin-enriched 
extracts were prepared and then subjected to immunoprecipitation with antibody against MSH6. After treatment of 
MSH2(WT), MSH2(D167H) and MSH2(K393M) cells with MNNG, we observed the formation of a MMR 
complex containing MLH1, MSH2, MSH6, and PCNA (Figure 2C). In contrast, MMR protein complex formation 
was not detectable in the MSH2(R524P) cell line, which is consistent with the inability of this mutant to localize to 
the chromatin. The inability of MSH2(P622L) to interact with MLH1 and PCNA is most likely due to a defect in 
protein stability and/or heterodimer formation with MSH6 that affects chromatin localization. 
 
MSH2 missense mutants alter the DNA checkpoint response to alkylation damage 
An intact DNA MMR pathway is required for activation of cell cycle checkpoints and apoptosis in response to 
low-doses of MNNG (Stojic, et al., 2004b). Therefore, to test if missense mutations in MSH2 could abrogate a 
normal DNA checkpoint response to MNNG we performed a colony survival assay.  A clear difference in 
resistance was observed between the vector only cells and MSH2(WT) cells at lower concentrations of MNNG 
(Figure 3).  Both MSH2(D167H) and MSH2(K393M) were able to restore  sensitivity to MNNG similar to 
MSH2(WT), while MSH2(R524P) and MSH2(P622L) were significantly more resistant than MSH2(WT) (Figure 
3). Furthermore, no significant difference in cell survival was observed for MSH2(R524P) and MSH2(P622L) 
compared to vector only cells. 
 
 
Figure 2. Chromatin localization and MMR protein complex formation of MSH2 missense mutants. Hec59 cells were 
synchronized with hydroxyurea (HU), treated with O
6-BG and 5 μM MNNG or DMSO for 1 h then returned to 
normal growth media. (A) Cell cycle progression was monitored by flow cytometry. (B) Chromatin-enriched extracts 
prepared from MNNG treated or control cells at 4h post-HU release subjected to analysis by SDS-PAGE and Western 
blotting using antibodies against MSH2, MLH1, and PCNA. H3 was used as a loading control. MSH2 and MLH1 
levels were quantified from at least three separate experiments and are reported as the average fold change over the 
MSH2(WT) levels in the absence of MNNG. (C) Chromatin-enriched extracts were subjected to ChIP analysis with 
antibody against MSH6 and interactions with MSH2, MLH1 and PCNA were probed by Western blot. NS refers to 
non-specific bands on the PCNA blot caused by the secondary antibody.  E1704   Mastrocola et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further dissect the function of these missense mutations in response to alkylation damage we monitored the 
induction of a G2 cell cycle arrest. By 48 h post-treatment the majority of cells expressing MSH2(WT), 
MSH2(D167H), and MSH2(K393M) arrested in the G2/M phase of the cell cycle (Figure 4A).  In general, vector 
only, MSH2(R524P), and MSH2(P622L)-expressing cells displayed unperturbed cell cycle profiles in response to 
MNNG (Figure 4A).  It has been reported that following induction of a G2 arrest, MMR-proficient cells treated 
with MNNG undergo apoptosis (Schroering and Williams, 2008). At 72 h there was a significant increase in the 
population of sub-G1 cells in the MSH2(WT), MSH2(D167H) and MSH2(K393M) lines compared to vector only, 
MSH2(R524P), and MSH2(P622L) suggesting increased apoptosis (Figure 4B).  
 
MSH2 missense mutations abrogate or diminish DNA MMR activity in vivo 
The repair capabilities of MSH2 missense mutations have been previously characterized using complementation 
assays in bacteria and resistance plate assays in yeast (Ellison, et al., 2001; Gammie, et al., 2007; Lützen, et al., 
2008; Martinez and Kolodner, 2010). Here, we have utilized an in vivo DNA mismatch repair assay in human cells 
(Zhou, et al., 2009). As expected, the vector only cell line was incapable of restoring EGFP fluorescence. By 
contrast, the number of EGFP positive MSH2(WT) cells increased greater than 10-fold (Figure 5). Both the 
MSH2(R524P) and MSH2(P622L) cell lines were unable to support MMR while the MSH2(D167H) expressing 
cells restored EGFP fluorescence similar to  WT (Figure 5).  MSH2(K393M) cells were appreciably more 
competent for repair than the vector only cells, though there was a slight, but significant decrease in repair 
compared to WT (Figure 5).  
 
Figure 3. MSH2 missense mutations alter sensitivity to DNA alkylation damage. (A) Response of 
wild-type and mutant MSH2 expressing cell lines treated with the indicated concentrations of 
MNNG was monitored by colony survival assays.  Survival curves for wild-type MSH2 expressing 
and vector-only
 control cells displayed in all three panels for comparison purposes.  (B) Survival 
curves for MSH2(D167H) and MSH2(K393M)  expressing cells.  (C) Survival curves for 
MSH2(R524P) and MSH2(P622L) expressing cells.  Experiments were performed in 
quadruplicate. In Vivo Functions Affected by MSH2 Missense Mutations  E1705 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
To date the functional characterization of MSH2 missense mutations has been performed in model organisms 
such as bacteria and yeast or in vitro (Ellison, et al., 2001; Gammie, et al., 2007; Heinen, et al., 2002; Lützen, et 
al., 2008; Martinez and Kolodner, 2010; Ollila, et al., 2008; Ollila, et al., 2006). Characterization of LS-associated 
missense mutations in MSH2 using a human expression system is limited (Belvederesi, et al., 2008; Ollila, et al., 
2006). Therefore, in our current study, we stably introduced four LS-associated missense mutations into the 
MSH2-null human endometrial cancer cell line Hec59 to determine their effects on in vivo cellular functions such 
as DNA repair and checkpoint response (Table 1). 
  In our previous in vitro biochemical studies of these four missense mutants, we had observed a modest 
reduction in binding of MSH2(D167H) and MSH2(K393M) to a small oligonucleotide duplex containing a 
mismatch and a significant decrease in sliding clamp formation on a circular, mismatched DNA template (Heinen, 
et al., 2002).  Consistent with these in vitro observations, we observed the accumulation of MSH2(D167H) and 
MSH2(K393M) on damaged chromatin to a slightly lesser extent compared to MSH2(WT). However, both 
mutants displayed increased sensitivity to DNA alkylation damage and increased repair over the vector only cells 
suggesting that the reduction in chromatin accumulation does not alter the DNA checkpoint response or repair 
efficiency. Interestingly, the level of repair observed in the MSH2(K393M) expressing cells was slightly reduced 
compared to the MSH2(WT) cells and may warrant further investigation.  
Figure 4. MSH2 missense mutants disrupt downstream responses to DNA alkylation damage. (A) 
Cell cycle progression of MNNG-treated wild type and mutant MSH2 expressing cells monitored 
by flow cytometry. (B) The sub-G1 population from cells at 72h post-treatment was quantified from 
two independent experiments. Asterisks indicate a p-value <0.05 by an unpaired t-test. E1706   Mastrocola et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this study MSH2 protein expression levels were similar to endogenous expression observed in equivalent 
amounts of HeLa extracts (data not shown).  However, the levels of mutant protein may still be higher than in 
tumors from an LS patient if they underwent a loss of heterozygosity (LOH) event and therefore express a 
hemizygous level of mutant protein.  It will be interesting to test whether reduced expression of MSH2(D167H) or 
MSH2(K393M) would result in defective MMR function compared to a similarly reduced level of wild-type 
MSH2. Additionally, it would be interesting to examine the variants in combination with other MMR gene 
variants. Recently it has been reported that the combination of weak MMR alleles in Saccharomyces cerevisiae 
produces a strong polygenic defect in MMR functions and suggests an important additional layer of genetic 
complexity (Martinez and Kolodner, 2010). This study demonstrated that the combination of the D164H allele 
(analogous to D167H in our study) with an msh6∆ mutation resulted in a slight increase in mutation rate.  Our data 
to this point, however, suggest that both variants are, at most, only very weakly contributing alleles.  
The inability of MSH2(R524P) to accumulate on damaged chromatin is entirely consistent with our previous in 
vitro analyses showing a defect in mismatch recognition (Heinen, et al., 2002). However, MSH2(R524P) 
chromatin localization during S-phase was similar to WT protein in undamaged cells.  This observation may reveal 
a damage-independent interaction between MSH2-MSH6 and chromatin that occurs normally during every S-
phase.  One possibility is that the MMR proteins are tethered to the newly synthesized chromatin during DNA 
replication to enhance the search for mismatches. Indeed this has been postulated as one of the consequences of 
MSH2-MSH6 interaction with PCNA (Lau and Kolodner, 2003), though an interaction between chromatin bound 
MSH2(R524P) and PCNA is barely detectable.  Analysis of MSH2(P622L) expression revealed a ~50% reduction 
with no detectable MSH6 and MSH3 protein, which taken together suggest a stability defect of the MSH2(P622L) 
protein which affects its ability to form a heterodimer with MSH6. These data are consistent with studies of the 
corresponding mutation in yeast Msh2 (P640L) (Gammie, et al., 2007).  However, two in vitro studies have shown 
that MSH2(P622L) and MSH6 interact to form a stable heterodimer (Heinen, et al., 2002; Lützen, et al., 2008).  
This discrepancy demonstrates the value of examining these mutant proteins in vivo in human cells. Importantly, 
both MSH2(R524P) and MSH2(P622L) were repair-deficient similar to the vector only cells, which taken together 
with the inability of these proteins to elicit a DNA checkpoint in response to DNA alkylation damage is strong 
evidence that the R524P and P622L MSH2 variants are pathogenic. 
 
 
 
 
Figure. 5. MSH2 missense mutations alter DNA mismatch repair activity in 
vivo. Mismatch repair was monitored in wild-type and mutant MSH2 
expressing cell lines transfected with a heteroduplex plasmid encoding EGFP 
with a premature stop codon and RFP as a transfection control. Flow 
cytometry data from at least two independent experiments was quantitated.  
The asterisk represents a p-value < .001 by an unpaired t-test. In Vivo Functions Affected by MSH2 Missense Mutations  E1707 
 
Table 1. Summary of MSH2 missense variant functional analyses 
 
(+)  Proficient compared to WT MSH2  
(-)   Deficient compared to WT MSH2 
(+/-) Reduced compared to WT MSH2 
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